Table 1.

Rodent models for human HFpEF research

Species	Comorbidity	Strain	Manipulation	Phenotypes
Rat	Hypertension	SHR		Hypertension and hypertrophy in 12 months HFpEF in 18 months
	Hypertension	Wistar	DOCA salt Unilateral nephrectomy 1% NaCl drinking water	Hypertrophy Severe hypertension
	Hypertension	DSS	4–8% NaCl chow	Severe hypertension Diastolic heart failure
Mouse	Hypertension	C57BL/6	DOCA salt Unilateral nephrectomy 1% NaCl drinking water	Mild hypertension Hypertrophy
	Hypertension	C57BL/6	Aldosterone Unilateral nephrectomy 1% NaCl drinking water	Hypertrophy Fibrosis Diastolic dysfunction
	Hypertension	C57BL/6	Pressure overload  TAC  AoB	Hypertrophy and fibrosis Diastolic dysfunction → systolic dysfunction
	Diabetes mellitus	db/db		Insulin resistance Hypertrophy Diastolic dysfunction
	Obesity	ob/ob		Hypertrophy Diastolic dysfunction
	Obesity + hypertension	C57BL/6	High-fat diet + L-NAME	Hypertrophy Diastolic dysfunction Pulmonary congestion
	Aging	SAMP		Diastolic dysfunction

The black arrow indicates the transition

AoB aortic banding, DOCA deoxycorticosterone acetate, DSS Dahl salt-sensitive, L-NAME L-NG-nitroarginine methyl ester, SAMP senescence-accelerated mouse prone 8, SHR spontaneous hypertensive rat, TAC transverse aortic constriction